Skip to main content

Animations

MJFF Publications

151 - 160 of 6422 Results
Title
Year
  • Year
  • 2009
  • 2024
  • 2024
  • 2024
  • 2008
  • 2025
  • 2021
  • 2025
  • 2025
  • 2025
  • Summary Details
    OPEN
    Title: Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models
    Journal Name: Disease Models & Mechanisms
    Publisher: The Company of Biologists
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1242/dmm.004267
    Citation Count: 178
  • Summary Details
    OPEN
    Title: Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior
    Journal Name: Neuron
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuron.2023.12.011
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Phosphoglycerate kinase is a central leverage point in Parkinson’s disease–driven neuronal metabolic deficits
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1126/sciadv.adn6016
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Dopamine neuron activity encodes the length of upcoming contralateral movement sequences
    Journal Name: Current Biology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.cub.2024.01.067
    Citation Count: 6
  • Summary Details
    OPEN
    Title: UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/nature07181
    Citation Count: 685
  • Summary Details
    OPEN
    Title: Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson’s disease
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.celrep.2025.115355
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Open science takes on Parkinson’s disease
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.7554/elife.66546
    Citation Count: 7
  • Summary Details
    OPEN
    Title: The bridge-like lipid transport protein VPS13C/PARK23 mediates ER–lysosome contacts following lysosome damage
    Journal Name: Nature Cell Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41556-025-01653-6
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1126/sciadv.adt2050
    Citation Count: 0
  • Summary Details
    OPEN
    Title: EndoMAP.v1 charts the structural landscape of human early endosome complexes
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41586-025-09059-y
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.